Rare stroke mechanisms in 4154 consecutive patients: causes, predictors, treatment, and outcomes.
Ischemic stroke
Rare stroke
Stroke mechanism
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
07
02
2022
accepted:
11
08
2022
pubmed:
23
8
2022
medline:
2
11
2022
entrez:
22
8
2022
Statut:
ppublish
Résumé
Rare mechanisms of stroke (RMS) in acute ischemic stroke (AIS) have rarely been studied applying a systematic approach. Our aim was to define the frequency, etiologies, predictors, and outcomes of RMS in a consecutive series of AIS. Data from consecutive patients from 2003 to 2016 were derived from the Acute STroke Registry and Analysis of Lausanne (ASTRAL). Frequency of subcategories of RMS was calculated. In a case-control design, RMS were compared to strokes of all other mechanisms. Outcome was assessed with 3-month Rankin-shift and 12-month mortality and recurrence rates. Out of 4154 AISs, 222 (5.3%) were found to have a RMS (42.0% female, median age 66 years). The most frequent RMS etiologies were medical interventions (25.6%), active oncological disease (22.5%), and vasculitis (11.7%). In multivariate analysis, RMS patients were younger, had more preceding and bilateral strokes, and a higher admission temperature. They were associated with less traditional risk factors and more systemic disease (such as AIDS, coagulopathy, and cancer). RMS also had more early ischemic changes on plain CT, less revascularization treatments, and more symptomatic hemorrhagic transformations. They presented significantly higher 3-month disability (Rankin-shift-OR RMS occurred in 5.3% of a large population of consecutive AISs and are most frequently related to medical interventions, cancer, and vasculitis. RMS patients have less traditional risk factors but more systemic comorbidities, hemorrhagic transformations, recurrences, and a worse long-term outcome. Identification of RMS has direct implications for early treatment and long-term outcome.
Sections du résumé
BACKGROUND
BACKGROUND
Rare mechanisms of stroke (RMS) in acute ischemic stroke (AIS) have rarely been studied applying a systematic approach. Our aim was to define the frequency, etiologies, predictors, and outcomes of RMS in a consecutive series of AIS.
METHODS
METHODS
Data from consecutive patients from 2003 to 2016 were derived from the Acute STroke Registry and Analysis of Lausanne (ASTRAL). Frequency of subcategories of RMS was calculated. In a case-control design, RMS were compared to strokes of all other mechanisms. Outcome was assessed with 3-month Rankin-shift and 12-month mortality and recurrence rates.
RESULTS
RESULTS
Out of 4154 AISs, 222 (5.3%) were found to have a RMS (42.0% female, median age 66 years). The most frequent RMS etiologies were medical interventions (25.6%), active oncological disease (22.5%), and vasculitis (11.7%). In multivariate analysis, RMS patients were younger, had more preceding and bilateral strokes, and a higher admission temperature. They were associated with less traditional risk factors and more systemic disease (such as AIDS, coagulopathy, and cancer). RMS also had more early ischemic changes on plain CT, less revascularization treatments, and more symptomatic hemorrhagic transformations. They presented significantly higher 3-month disability (Rankin-shift-OR
CONCLUSIONS
CONCLUSIONS
RMS occurred in 5.3% of a large population of consecutive AISs and are most frequently related to medical interventions, cancer, and vasculitis. RMS patients have less traditional risk factors but more systemic comorbidities, hemorrhagic transformations, recurrences, and a worse long-term outcome. Identification of RMS has direct implications for early treatment and long-term outcome.
Identifiants
pubmed: 35994133
doi: 10.1007/s10072-022-06344-w
pii: 10.1007/s10072-022-06344-w
pmc: PMC9616760
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6359-6369Informations de copyright
© 2022. The Author(s).
Références
Stroke. 1989 May;20(5):583-91
pubmed: 2718197
Ann Thorac Surg. 2000 Apr;69(4):1053-6
pubmed: 10800793
Stroke. 2020 May;51(5):1419-1427
pubmed: 32279620
Eur Heart J. 2007 May;28(9):1155-61
pubmed: 17363448
Stroke. 2014 Jul;45(7):2160-236
pubmed: 24788967
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
N Engl J Med. 1995 Apr 6;332(14):912-7
pubmed: 7877648
Eur J Neurol. 2001 Mar;8(2):133-9
pubmed: 11430270
Ann Neurol. 2018 May;83(5):873-883
pubmed: 29633334
Stroke. 2008 Sep;39(9):2485-90
pubmed: 18617663
Cerebrovasc Dis. 1998 Sep-Oct;8(5):278-88
pubmed: 9712926
Arthritis Rheum. 2008 Aug 15;59(8):1090-6
pubmed: 18668583
Rheumatol Int. 2015 May;35(5):905-9
pubmed: 25354465
Stroke. 2017 May;48(5):1248-1255
pubmed: 28330942
Ann Neurol. 1995 Jul;38(1):119-24
pubmed: 7611714
Stroke. 2010 Nov;41(11):2491-8
pubmed: 20930152
Cerebrovasc Dis. 2008;25(5):457-507
pubmed: 18477843
Stroke. 2018 Apr;49(4):814-819
pubmed: 29535272
Stroke. 2002 Sep;33(9):2243-6
pubmed: 12215594
Lancet Neurol. 2014 Apr;13(4):429-38
pubmed: 24646875
Neurology. 2015 Aug 11;85(6):505-11
pubmed: 26180146
Cancer Treat Rev. 2017 Jan;52:58-70
pubmed: 27894012
Ann Neurol. 2007 Nov;62(5):442-51
pubmed: 17924545
Lancet Neurol. 2009 Jul;8(7):668-78
pubmed: 19539238
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Neurology. 2000 Feb 22;54(4):883-9
pubmed: 10690981
Eur Neurol. 1997;38(1):10-20
pubmed: 9252793
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
Neurology. 2013 Aug 13;81(7):619-25
pubmed: 23864310
Stroke. 2002 Jan;33(1):51-6
pubmed: 11779888
J Stroke Cerebrovasc Dis. 2016 Apr;25(4):781-91
pubmed: 26775269
Lancet. 1998 Oct 17;352(9136):1245-51
pubmed: 9788453
Neurology. 1988 Mar;38(3):352-9
pubmed: 3347337